Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly teams with ImmuNext for autoimmune drug

by Lisa M. Jarvis
March 29, 2019 | A version of this story appeared in Volume 97, Issue 13

 

Eli Lilly and Company will pay ImmuNext $40 million as part of a research pact focused on an autoimmune disease drug target. The companies have not identified the target but note that most autoimmune therapies dampen the immune system’s response, whereas they want to develop an antibody that can reprogram the immune system. Under the deal, which could be worth $565 million for ImmuNext if products reach the market, Lilly gets a license on a target related to metabolism of white blood cells.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.